drankitjoshi/Post-NAHT-Prostate-Cancer-Outcome-Predictor

1{
2  "recommended_bcr_model": "bcr_clinical",
3  "deployable_models": [
4    {
5      "name": "bcr_clinical",
6      "outcome": "BCR_binary",
7      "deployable": true,
8      "exploratory": false,
9      "features": [
10        "AGE(yrs)",
11        "Initial PSA (ng/ml)",
12        "Gleason Grade Group",
13        "PROSTATE SIZE (ml)",
14        "Pre_T_stage_numeric",
15        "Pre_N1",
16        "High_risk_features_count",
17        "PSA_reduction_pct",
18        "Volume_reduction_pct",
19        "PSA_normalized",
20        "Post_T_stage_numeric",
21        "T_stage_downstaged"
22      ],
23      "note": "Clinical BCR model using pre/post-NAHT variables only."
24    },
25    {
26      "name": "margin",
27      "outcome": "Margin_positive",
28      "deployable": true,
29      "exploratory": false,
30      "features": [
31        "AGE(yrs)",
32        "Initial PSA (ng/ml)",
33        "Gleason Grade Group",
34        "PROSTATE SIZE (ml)",
35        "Pre_T_stage_numeric",
36        "Pre_N1",
37        "High_risk_features_count",
38        "PSA_reduction_pct",
39        "Volume_reduction_pct",
40        "PSA_normalized",
41        "Post_T_stage_numeric",
42        "T_stage_downstaged"
43      ],
44      "note": "Positive surgical margin prediction."
45    },
46    {
47      "name": "pcr",
48      "outcome": "pCR",
49      "deployable": true,
50      "exploratory": true,
51      "features": [
52        "AGE(yrs)",
53        "Initial PSA (ng/ml)",
54        "Gleason Grade Group",
55        "PROSTATE SIZE (ml)",
56        "Pre_T_stage_numeric",
57        "Pre_N1",
58        "High_risk_features_count",
59        "PSA_reduction_pct",
60        "Volume_reduction_pct",
61        "PSA_normalized",
62        "Post_T_stage_numeric",
63        "T_stage_downstaged"
64      ],
65      "note": "Pathological complete response prediction."
66    },
67    {
68      "name": "node",
69      "outcome": "Node_positive",
70      "deployable": true,
71      "exploratory": false,
72      "features": [
73        "AGE(yrs)",
74        "Initial PSA (ng/ml)",
75        "Gleason Grade Group",
76        "PROSTATE SIZE (ml)",
77        "Pre_T_stage_numeric",
78        "Pre_N1",
79        "High_risk_features_count",
80        "PSA_reduction_pct",
81        "Volume_reduction_pct",
82        "PSA_normalized",
83        "Post_T_stage_numeric",
84        "T_stage_downstaged"
85      ],
86      "note": "Pathological node positivity prediction."
87    }
88  ],
89  "app_note": "The clinical app should use bcr_clinical for BCR risk. bcr_postop should remain manuscript/postoperative only because it depends on pathology.",
90  "survival_models": [
91    {
92      "name": "cox_bcr_clinical",
93      "outcome": "BCR_binary",
94      "duration": "BCR_time_months",
95      "features": [
96        "AGE(yrs)",
97        "Initial PSA (ng/ml)",
98        "Gleason Grade Group",
99        "PROSTATE SIZE (ml)",
100        "Pre_T_stage_numeric",
101        "Pre_N1",
102        "High_risk_features_count",
103        "PSA_reduction_pct",
104        "Volume_reduction_pct",
105        "PSA_normalized",
106        "Post_T_stage_numeric",
107        "T_stage_downstaged"
108      ],
109      "landmark_months": [
110        12,
111        24,
112        36,
113        60
114      ],
115      "risk_group_labels": [
116        "Low Risk",
117        "Medium Risk",
118        "High Risk"
119      ],
120      "risk_cutoffs": [
121        -0.43707978498149164,
122        0.39894003971384095
123      ],
124      "note": "Clinical Cox model for BCR-free survival using pre/post-NAHT variables only."
125    }
126  ],
127  "survival_note": "The deployable survival component is a clinical Cox model for BCR-free survival using pre/post-NAHT variables only."
128}